anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants (n=6 per cohort) will be administered 2 injections (Day 0 and Day 3) of INO-A002 at 2 mg DNA/dose. Inoculation will be administered as 1 ml IM injection followed by electroporation with the CELLECTRA® 2000 device.
In addition to SBT, participants will aim to eliminate all meat, poultry, and fish from their diet over the first 6 weeks, and will be taught how to select appropriate substitutes for these foods, such as low- or no-fat dairy products (cheeses, milk), and protein-containing vegetable sources (soy products, legumes). .
The SBRT of all metastases should start in maximum 4 weeks after randomization. Beginning of systemic treatment will take place before 2 and 7 days after SBRT completion. All metastases lesions should be treated every 48h.
Soft-tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin and account for only 1% of adult malignancies. They tend to occur most commonly in the lower extremities. Reconstruction after sarcoma resection can be challenging, especially when important structures are involved and recurrences occur. Additionally, more attention is now being paid to reconstructing the lymphatic system to prevent lymphatic complications. In this case report, we presented the management of recurrent medial thigh sarcoma that necessitated multiple challenging reconstructions to provide valuable insights for lectures on similar cases. A 50-year-old male patient was diagnosed with an undifferentiated pleomorphic cell sarcoma (UPS) of the anteromedial thigh. After preoperative radiotherapy, a mass of 23 × 15 cm was removed, and reconstruction with a pedicled deep inferior epigastric artery perforator (p-DIEP) flap-based lymphatic flow through (LyFT) was performed. Six months later, the patient developed the first local recurrence with the presence of a distant metastasis. Following the tumor resection, the medial part of the DIEP flap was de-epithelized and buried in the defect for dead space obliteration. Another local recurrence arose 7 months after the second surgery. Therefore, a major debulking surgery involving the femoral neurovascular bundle was performed. The femoral artery was reconstructed with a synthetic graft, and the femoral vein with the great saphenous vein harvested from the contralateral thigh. A composite myocutaneous neurotized anterolateral thigh (ALT) flap from the contralateral thigh was used to obliterate the defect and restore the loss of function of the quadriceps femoris. Two lymphaticovenular anastomoses (LVAs) were performed at the ankle to reduce the risk of lymphatic sequelae. This case report highlights the importance of integrating various techniques to create a tailored approach that effectively addresses complex surgical requirements to avoid limb amputation and maintain functionality.
The invention discloses a chimera of an autophagy targeting nano antibody and application thereof, and belongs to the technical field of targeted protein degradation. In order to better solve the technical problem of selectively degrading various targets in cells. The autophagy antibody provided by the invention is a target head containing a nano-antibody target head and a target cell autophagy process, and different targets can be degraded only by changing the nano-antibody target head. The invention also discloses the combination of autophagy antibodies with chemically induced proximity techniques to achieve conditional degradation of intracellular targets with small molecules. The invention also discloses SNACIP drugs which are designed to penetrate membranes based on autophagy antibodies, and intracellular targets can be degraded by drug addition. The technology has a broader substrate category than proteasome-based degradation means, and can degrade targets other than soluble proteins, including organelles, and the like.
This study investigated the effects of Selenium (Se) on testis toxicity induced by Acrylamide (ACR) in rats. In our study, 50 male adult rats were used, and the rats were divided into five groups; control, ACR, Se0.5 + ACR, Se1 + ACR, and Se1. Se and ACR treatments were applied for 10 days. On the 11th day of the experimental study, intracardiac blood samples from the rats were taken under anesthesia and euthanized. Sperm motility and morphology were evaluated. Dihydrotestosterone, FSH, and LH levels in sera were analyzed with commercial ELISA kits. MDA, GSH, TNF-α, IL-6, and IL-1β levels and SOD, GPx, and CAT, activities were measured to detect the level of oxidative stress and inflammation in rat testis tissues. Expression analysis of HSD17B1, StAR, CYP17A1, MAPk14, and P-53 as target mRNA levels were performed with Real Time-PCR System technology for each cDNA sample synthesized from rat testis RNA. Testicular tissues were evaluated by histopathological, immunohistochemical, and immunofluorescent examinations. Serum dihydrotestosterone and FSH levels decreased significantly in the ACR group compared to the control group, while LH levels increased and a high dose of Se prevented these changes caused by ACR. A high dose of Se prevented these changes caused by ACR. ACR-induced testicular oxidative stress, inflammation, apoptosis, changes in the expression of reproductive enzymes, some changes in sperm motility and morphology, DNA, and tissue damage, and Se administration prevented these pathologies caused by ACR. As a result of this study, it was determined that Se prevents oxidative stress, inflammation, apoptosis, autophagy, and DNA damage in testicular toxicity induced by ACR in rats.
Neuromodulation by means of vagus nerve stimulation (VNS) therapy, reduces seizure frequency and improves quality of life in subjects with drug-resistant epilepsy (DRE), yet its molecular mechanism remains unclear. This study investigates the impact of chronic VNS on lipid bioactive metabolites and fatty acids (FA) in the plasma and red blood cells of seven subjects with DRE. By measuring expression levels of peroxisome proliferator-activated receptor α (PPARα) and sirtuin1 (SIRT1) genes-key regulators in energy and lipid metabolism-and lipid profiles before and after various stages of VNS, this study identifies potential mechanisms by which VNS may reduce seizure frequency. Blood samples collected before VNS device implantation, after acute VNS stimulus, and following gradual intensity increments up to therapeutic levels revealed that VNS increases SIRT1 and PPARα expression and erythrocyte concentrations of PPARα ligands. Additionally, we observe reduced de novo lipogenesis biomarkers in erythrocytes, indicating that VNS may influence systemic lipid and energy metabolism. Our findings suggest that VNS could enhance neuronal function by modulating energy metabolism, thus potentially reducing seizure frequency in subjects with DRE. Future research targeting SIRT1 and PPARα may provide innovative therapeutic strategies for managing DRE. Plain Language Summary: The exact mechanism of VNS is still unknown. This study investigated the effects of VNS Therapy on energetic metabolism, suggesting possible novel biomarkers for DRE subjects and neuromodulation therapies.
The method includes nasal application of human semiochemical compounds, e.g. Androstane steroids or a pharmaceutical composition containing them. The compositions secure the adjunction of the semiochemical binder to a specific neuroepithelial receptor. Preferably the steroid (or steroids) are introduced in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other alternatives of the invention include pharmacuetical compositions contining steroids having the formula: where R1 is selected from the group containing oxo, alpha-(beta)hydroxy, alpha-(beta-)acetoxy, alpha(beta-)propionoxy, alpha(beta-)methoxy, alpha(beta-)lower molecular acyloxy, alpha(beta-)low molecular alkyloxy and alpha(beta-)benzyloxy; R2 is of the group consisting of methyl, hydroxymethyl, acyloxymethyl, alkoxymetyl, low molecular alkyl, hydroxyalkyl, acyloxyalkyl and alkoxyalkyl, R3 is missing or is selected from the group consisting of methyl, hydroxymethyl, acyloxymethyl, alkoxymethyl, low molecular alkyl, hydroxyalkyl, acyloxyalkyl and alkoxyalkyl; R4 is selected from the group of hydrogen, oxo, halo, hydroxy, alkoxy and acyloxy; R5 in one or two substituents including one or two hydrogen atoms, methyl methylene, or one or two halogen atoms and R6 is hydrogen or halo; and a,b,c, d, e, f,h are opposite places for noncompulsory double bonds. 77 claims, 11 figures
FIELD: medicinal molecular biology, peptides, pharmacy. SUBSTANCE: invention relates to novel peptide sequences and their analogues showing properties of agonists of apolipoprotein A-1 (Apo-A-1) by their administration in effective doses to patient. Such analogues are used for treatment of different disorders associated with dyslipidemia. Invention comprises data about corresponding chemical structures, different complexes of such lipids, in part, with lipids as component pharmaceutical compositions and methods for treatment of dyslipidemic disorders. EFFECT: expanded assortment of agents in therapy of different dyslipidemic states. 51 cl, 10 tbl, 10 dwg
<P>PROBLEM TO BE SOLVED: To provide an external preparation for skin capable of providing sufficient viscosity by a simple operation and excellent in feelings upon use in a salt type agent formulation system.  <P>SOLUTION: The external preparation for skin is obtained by formulating a salt type agent with xanthan gum and guar gum. It is preferable for the external preparation that the weight ratio of the xanthan gum to the guar gum is (10:90) to (90:10), further (20:80) to (80:20). The external preparation for skin is excellent in viscosity stability at high temperature when the weight ratio is particularly (50:50) to (20:80). The salt type agent is preferably an ascorbic acid-based and/or alkoxysalicylic acid-based bleaching agent.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Arm I provides one dose of RO70097890 as a single agent in the neoadjuvant setting. Patients will recover from any toxicities and will then have their disease surgically resected. After recovery from surgery patients will proceed to adjuvant therapy which will include nab-paclitaxel 125mg/m2 and gemcitabine 1000mg/m2 on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle. Four cycles of adjuvant therapy will be given. All medications are administered intravenously.
Five IV infusions of autologous, adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety lab follow ups at weeks 6, 14, 26; inflammatory marker follow ups at weeks 6, 14, 26; SF-36 and PHQ-9 Questionnaires at weeks 2, 6, 10, 14, 18, 22, 26.
The Mindfulness intervention will consist of six 2-hour sessions that will include guided mindfulness practices, didactics, and group discussion. The course curriculum is modeled on the Mindfulness-Based Stress Reduction program which involves intensive experiential training of participants in secular mindfulness meditation practices (i.e., body scan, sitting meditation, gentle hatha yoga with chair adaptations, compassion meditation), with an emphasis on embodying interpersonal mindfulness in dialogue.
BACKGROUND: Keloid, a prevalent pathological skin lesion, presents significant challenges in terms of treatment efficacy. Photodynamic therapy (PDT), an increasingly popular adjuvant treatment, has shown significant potential in the management of various disorders, including cancer. However, the therapeutic potential of indocyanine green-mediated photodynamic therapy (ICG-PDT) for keloids has not yet been demonstrated.
METHODS: In this study, we divided the experimental groups into control group, Photothermal Therapy group, Photodynamic Therapy group, and Combined Therapy group. The in vitro investigation aimed to optimize the clinical application of PDT for keloid treatment by elucidating its underlying mechanism. Subsequently, on this basis, we endeavored to manage a clinical case of keloid by employing surgical intervention in conjunction with modified ICG-PDT.
RESULTS: Our investigation revealed an unexpected outcome that ICG-PDT maximally inhibited the cellular activity and migration of keloid fibroblasts only when photodynamic mechanism took effect. Additionally, the induction of autophagy and apoptosis, as well as the inhibition of collagen synthesis, were particularly evident in this experimental group. Furthermore, the above therapeutic effect could be achieved at remarkably low drug concentrations. Building upon the aforementioned experimental findings, we successfully optimized the treatment modality for the latest case and obtained a more favorable treatment outcome.
CONCLUSIONS: This study investigated the mechanism of ICG-PDT treatment and optimized the in vivo treatment regimen, demonstrating the significant therapeutic potential of ICG-PDT treatment in clinical keloid treatment.
The invention discloses a sunburnt skin repair strip applying a novel matrix material and a preparation method thereof. The sunburnt skin repair strip comprises the following main ingredients: licorice extract, mulberry extract, chamomile oil, aloe oil and vitamin C derivatives. The sunburnt skin repair strip adopts an adhesive composed of a novel elastomer material styrene-isoprene-styrene (SIS) triblock copolymer, a tackifier and a plasticizer as a cosmetic matrix material. In the invention, the preparation process of the novel strip for external use adopts the low-temperature online melting forming technology. The prepared sunburnt skin repair strip can obviously improve the damaged skin on the face and has the multiple effects of cooling the skin, diminishing inflammation, whitening the skin, preserving moisture, relieving the skin, resisting the radicals and the like. The sunburnt skin repair strip can penetrate into the skin layer and relieve dryness, tingle, allergy and the like of the sunburnt skin. The sunburnt skin repair strip is safe and is not irritative.
An extract of  Asplenium nidus L . includes pyropheophorbide a methyl ester (C 34 H 36 N 4 O 3 ), pheophorbide a methyl ester (C 35 H 36 N 4 O 5 ), 1-linleoyl-3-linolenoyl-glycerol (C 39 H 66 O 5 ), 1-linleoyl-2,3-dipalmitoyl-rac-glycerol (C 53 H 98 O 6 ) and 1,3-dipalmitoyl-sn-glycerol (C 35 H 68 O 5 ). The extract of  Asplenium nidus L . is obtained by using a method including steps of: solvent extraction, using an solvent to extract an  Asplenium nidus L . sample and to obtain an extract, with a w/v ratio between the solvent and the  Asplenium nidus L . sample being 50˜60 mg/ml; and column chromatography, fractionating the extract with water and ethanol as eluent to obtain several fractions including fraction a to fraction i, and further evaporating and lyophilizing fraction b, c, d or their combination to obtain an extract of  Asplenium nidus L .
Porokeratosis ptychotropica (PP) is a rare and unusual variant of porokeratosis. There is a dearth of information on the natural history, epidemiology, and optimal treatment options. This study aimed to characterize the worldwide distribution, epidemiology, clinical features, and treatments attempted for all reported cases of porokeratosis ptychotropica. A total of 59 cases of porokeratosis ptychotropica have been reported, with most cases originating from the United States. The median age of patients affected with porokeratosis ptychotropica was 49 years. The most involved body locations are the buttocks and gluteal cleft. The risk of malignant transformation in porokeratosis ptychotropica is approximately 1.7% but there is significant bias in estimating rare occurrences in rare diseases. In conclusion, PP is an important but under-recognized variant of porokeratosis, with a likely low risk of malignant transformation. The best available treatment modality remains uncertain; however, the use of topical lovastatin/cholesterol cream appears promising. Long-term surveillance appears prudent for porokeratosis ptychotropica due to a risk of cancerization.
Teratogenic Effects. Pregnancy Category C – Hydrocodone has been shown to be teratogenic in hamsters when given in doses 700 times the human dose. There are no adequate and well-controlled studies in pregnant women. TussiCaps® extended-release capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects – Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.
For patients randomized to the intervention group, once the dose of background norepinephrine reaches ≥0.2 mcg/kg/min for ≥30 minutes, angiotensin II will be started at a dose of 20 ng/kg/min (recommended starting dose in package insert). Thereafter, angiotensin II and norepinephrine will both be titrated according to the schema in UNM Hospitals Nursing Department Titration Guideline. Angiotensin II treatment will be capped at 72h, at which point (if a second vasopressor is still needed) the patient will be started on an alternative agent.
PURPOSE:To provide a calcium agent consisting of fine powder of egg shell pulverized at a low temperature, or a formed product of the powder. CONSTITUTION:A fresh egg is broken and the shell is separated from the content. The shell is washed as soon as possible with warm water or cold water, and dried keeping the shell temperature to <80 deg.C. The dried shell is pulverized taking care of preventing the increase of the shell temperature above 80 deg.C by the heat of friction, etc. The crushed shell is sieved with a 300 mesh sieve to obtain purely white fine powder of a calcium agent. 85% of the powder passes through the sieve. The agent is taken by scooping with a spoon, or wrapped in a wafer. Since the shell is not exposed to a high temperature during the processing, the thermal degradation of minerals can be prevented, and the living active microorganisms attack the pathogenic bacteria and promote the action of the cells. Combination of vitamin D improves the absorption of calcium.
Recombinant lentiviral vectors having a region encoding a functional globin gene; and large portions of the beta-globin locus control regions which include DNase I hypersensitive sites HS2, HS3 and HS4 provides expression of beta-globin when introduced into a mammal, for example a human, in vivo. Optionally, the vector further includes a region encoding a dihydrofolate reductase. The vector may be used in treatment of hemoglobinopathies, including beta-thalessemia and sickle-cell disease. For example, hematopoietic progenitor or stem cells may be transformed ex vivo and then restored to the patient. Selection processes may be used to increase the percentage of transformed cells in the returned population. For example, a selection marker which makes transformed cells more drug resistant than un-transformed cells allows selection by treatment of the cells with the corresponding drug.
Breastfeeding is the ideal infant nutrition recommended by governmental and medical professional organizations. Its benefits to infants and their mothers are many including protection from infections, certain malignancies and chronic diseases, as well as improved growth, development, cognition and intelligence for children. Yet, women with inverted nipples often face difficulties in breastfeeding that ultimately force them to prematurely terminate breastfeeding. The main treatment of severely inverted nipples is surgical sectioning of the lactiferous ducts at the expense of breast's function. Several conservative measures have also been used for the less severe (grades 1 and 2) inverted nipples such as application of Hoffman Exercises and Woolwich Breast Shields, which have failed to prove their worth. The modified syringe technique is a conservative means for the correction of inverted nipples that was reported in a single case series of 8 women, with high success rates in infant latching (7/8) and exclusive breastfeeding (6/8). It is a simple, inexpensive, portable, safe, and easily learned method that can be performed by mothers as often as required.

This open-label randomized clinical trial aims to investigate the effectiveness of the use of inverted syringe on the 1-month exclusive breastfeeding rate in women with inverted nipples. We hypothesize that in women with grades 1 and 2 inverted nipples, the use of the modified syringe technique soon after delivery, as opposed to the standard of care, will significantly improve breastfeeding rates at 1 month postpartum. We will recruit 100 healthy women at ≥37 weeks of gestation with grades 1 or 2 inverted nipples from the Women's Health Center and the obstetrics outpatient department at AUBMC. They will be randomly allocated to a control group (standard of care) or to the intervention group (inverted syringe). Data will be collected at baseline (socio-demographic variables, inverted nipple grading) and at 1, 3, and 7 days postpartum about infant feeding method, and adverse events. Mothers will be contacted at 1, 3 and 6 months regarding infant feeding method, maternal satisfaction, infant's weight gain and adverse events. The association between breastfeeding success at 1 month and the use of the inverted syringe will be investigated using multivariate regression models. Findings from this study, if positive, will provide much needed evidence for a safe, affordable, readily available and simple intervention to treat inverted nipples and improve breastfeeding practice among affected women.
Acupuncture point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete.
BACKGROUND: Patient reported experience measures are contemporary quality indicators that focus on evaluation of healthcare delivery processes. While surgical arteriovenous fistulas (otherAVF) are preferred for haemodialysis vascular access, fears about surgery and complications often result in refusal/delays. A new technique of endovascular arteriovenous fistula creation (EndoAVF) has been developed and as part of it's ongoing introduction into our unit, the patient perspective was felt critical to its evaluation. The Vascular Access Questionnaire (VAQ) provides a mechanism for identifying and scoring perceptions in this setting.
METHOD: Patients who had previously undergone EndoAVF formation were approached to undertake the VAQ as part of a service evaluation of their experience. In addition to the components of the VAQ, data questions relating to the patient's perception of their access were gathered. Results were compared with a matched historical cohort of surgically created fistulas (otherAVF) patients.
RESULTS: Patient satisfaction and self-reported ease of use with EndoAVF were high. Overall VAQ scores were similar between the EndoAVF and the surgically created cohort. Functionally, there was no significant difference in perception of their fistula by patients, irrespective of them being created surgically or radiologically.
CONCLUSION: Although numbers in this report are small limiting exploration of preserved inherent heterogeneity, we provide a useful initial patient reported experience and perspectives on comparative functional use of radiologically and surgically created AVFs. As real world experience gathers, future larger cohorts with adequate sampling may allow exploration of patient reported experiences and outcome measures.